WuXi PharmaTech's Genome Center is now offering analysis services from NextCode Health, a bioinformatics company in Cambridge, Mass., which will provide population-scale genome analysis. NextCode will work with the WuXi Genome Center to process sequence data from WuXi's customers and produce a report discussing the medical implications.
The Dana-Farber Cancer Institute and the Brigham and Women's Cancer Center have a launched Rapid Heme Panel, a next-gen sequencing-based panel that analyzes alterations in 95 genes that are frequently associated with leukemias and myeloid disorders. The test has a turnaround time of five business days.
Enzymatics has launched Archer Assay Designer, a software platform to design custom primer panels to generate target-enriched libraries in order to identify gene fusions through next-gen sequencing. The software allows the user to search for genes and exons of interest.
Almac Group has launched a CLIA validated next-gen sequencing assay for P53 mutations. The test can be run on formalin-fixed paraffin-embedded samples and covers all coding regions and upstream regulatory regions of P53.
Swift Biosciences has launched an early access program for its next-generation sequencing-based TP53 Panel that covers all coding exons of the gene. The panel uses Swift's Accel-NGS Amplicon Panel technology and runs on Illumina's sequencing instruments. In addition, it is planning another panel using the Accel-NGS Ampliocn technology that will target over 200 clinically relevant cancer mutations.